Latest Interviews
"Identifying drugs has been straightforward: we look for well-characterized drugs originally developed by other companies and intended for other disease states. Because they already have extensive clinical and pre-clinical data, we have been able to take these drugs directly into Phase 2 proof of concept studies in targeted orphan diseases."
55956
“By the end of 2017, we identified eight novel targets and have selected three for drug discovery. We now have three full drug discovery programs centering on these new targets.”
55948
"Battery-charging technologies should be used in a similar way to cellphones, regardless of the brand"
55943
Michael Bigham: CEO and Chairman of the Board
Evan Loh: President, Chief Operating Officer and Chief Medical Officer
55938
"Brenntag Mexico is on a solid growth path, which requires investment to expand the capacity for bulk and packaged chemicals and supports the growth of the key industries for the country."
55936
"The previous company was too aggressive in their development plan. They went underground on limited drilling meaning they had not defined the resource in detail so it was difficult for the mining engineers to develop a thorough plan. Also, the targeted throughput rate of 1,000 mt/d was too high for the size of the deposit."